Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1 6Phase 3 3Phase 2/3 3Phase 1/2 2Phase EARLY_PHASE1 1Phase 4 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Neoplasms 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Interventional × entrectinib × Clear all
NCT05862285 2026-05-12

UmbrellaMAX

Hoffmann-La Roche

Phase 3 Recruiting
100 enrolled
Tumor-Agnostic

Neoplasms

NCT05170204 2026-05-06

HORIZON 1

Hoffmann-La Roche

Phase 3 Active not recruiting
68 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04603807 2026-02-27

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

Hoffmann-La Roche

Phase 3 Active not recruiting
220 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡